FBT:NYE-First Trust NYSE Arca Biotechnology Index Fund (USD)

ETF | Health |

Last Closing

USD 165.9908

Change

+1.55 (+0.94)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-02 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.96 (+0.67%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

+0.53 (+0.79%)

USD 2.70B
FXH First Trust Health Care AlphaD..

+0.61 (+0.59%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

+1.24 (+1.52%)

USD 0.18B
IDNA iShares Genomics Immunology an..

+0.42 (+2.08%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.78 (+2.89%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+0.46 (+0.47%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.32 (+1.18%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.34 (+2.36%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.72 (+4.36%)

USD 0.01B

ETFs Containing FBT

FHM:CA 0.00 % 0.78 %

N/A

N/A
FBT:CA First Trust NYSE Arca Bio.. 0.00 % 0.00 %

-1.13 (-3.67%)

CAD 1.83M

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.13% 52% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.13% 52% F 51% F
Trailing 12 Months  
Capital Gain 9.21% 100% F 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.21% 100% F 68% D+
Trailing 5 Years  
Capital Gain 28.27% 38% F 37% F
Dividend Return 1.71% 37% F 3% F
Total Return 29.98% 38% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain 0.91% 38% F 38% F
Dividend Return 1.24% 38% F 28% F
Total Return 0.33% 42% F 9% A-
Risk Return Profile  
Volatility (Standard Deviation) 11.61% 86% B+ 75% C
Risk Adjusted Return 10.70% 38% F 28% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.